Tags |
|
|
Links |
|
|
Top Articles - Sarbanes Oxley Compliance
The U.S. House of Representatives passed The Sarbanes-Oxley Act in 2002. It seeks to bring in better ethics and accountability in
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
the operations of companies in the United States
The Sarbanes-Oxley Actrequires companies to disclose internal controls, ethics
The Sarbanes-Oxley Actrequires companies to disclose internal controls, ethics
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
codes and the structure of their audit committees on annual reports. Most businesses today make use of information technology fo
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
r all their financial reporting processes. Data, documents and other key operational processes are managed electronically. Inform
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
ation Technology plays a vital role in internal control. Chief information officers are responsible for the security, accuracy an
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
d the reliability of systems that manage and report financial data. Although the Act places responsibility in corporate financial
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
reporting on the chief executive officer (CEO) and chief financial officer (CFO), the chief information officer (CIO) also plays
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
a significant role in financial reporting.
The Act requires a company to perform a self-assessment of risks for business proce
The Act requires a company to perform a self-assessment of risks for business proce
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
sses that affect financial reporting. All business records and electronic messages are to be saved for not less than five years.
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
The consequences for non-compliance are fines, imprisonment, or both.
The PCAOB rendered that the management of all companies us
The PCAOB rendered that the management of all companies us
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
e an internal control framework standard such as the Committee of Sponsoring Organizations of the Treadway Commission. The stand
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
ard describes how to assess the control environment, determine control objectives, perform risk assesments, identify controls and
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
monitor compliance.
Section 302 of the Sarbanes-Oxley Act makes it mandatory for a set of internal procedures to be designed to
Section 302 of the Sarbanes-Oxley Act makes it mandatory for a set of internal procedures to be designed to
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ensure accurate financial disclosure. The signing officers must certify that they are responsible for establishing and maintaini
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
ng internal controls. They must also certify that they have designed internal controls to ensure that material information relati
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
ng to the company is made known to other officers.
Under Section 404 of the Act, the management of a company is required to pro
Under Section 404 of the Act, the management of a company is required to pro
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
duce an internal control report as part of each annual Exchange Act report. The report must reaffirm the responsibility of the ma
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
nagement in establishing and maintaining adequate internal control structures and procedures for financial reporting. The report
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
must also contain an assessment of the effectiveness of the internal control structure. All corporations operating in the Unite
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
d States should take steps to understand the Sarbanes-Oxley Actin minute detail to ensure that steps are taken to comply with it.
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/131292/toparticles-Sarbanes-Oxley-Compliance.html">Sarbanes Oxley Compliance</a>
BB link (for phorums):
[url=http://www.toparticles.org.ua/article/131292/toparticles-Sarbanes-Oxley-Compliance.html]Sarbanes Oxley Compliance[/url]
Related Articles:
Real Estate Marketing Strategies: How to Attract Your Ideal Client
Search Engine Robots - How They Work, What They Do (Part II)
Bookmark it:
|